Literature DB >> 18050300

Safe use of infliximab for the treatment of fistulizing Crohn's disease during pregnancy within 3 months of conception.

Erika Angelucci, Andrea Cocco, Angelo Viscido, Renzo Caprilli.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18050300     DOI: 10.1002/ibd.20319

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


× No keyword cloud information.
  6 in total

1.  Safety of Tumor Necrosis Factor Inhibitors during Pregnancy and Breastfeeding.

Authors:  Harish Raja; Eric L Matteson; Clement J Michet; Justine R Smith; Jose S Pulido
Journal:  Transl Vis Sci Technol       Date:  2012-09-21       Impact factor: 3.283

2.  The use of anti-TNFα medications for rheumatologic disease in pregnancy.

Authors:  Megan Eb Clowse
Journal:  Int J Womens Health       Date:  2010-08-09

Review 3.  Tumor necrosis factor-α inhibitor therapy and fetal risk: a systematic literature review.

Authors:  Renée M Marchioni; Gary R Lichtenstein
Journal:  World J Gastroenterol       Date:  2013-05-07       Impact factor: 5.742

Review 4.  From conception to delivery: managing the pregnant inflammatory bowel disease patient.

Authors:  Vivian W Huang; Flavio M Habal
Journal:  World J Gastroenterol       Date:  2014-04-07       Impact factor: 5.742

Review 5.  Safety of TNF-α inhibitors during IBD pregnancy: a systematic review.

Authors:  Ole Haagen Nielsen; Edward V Loftus; Tine Jess
Journal:  BMC Med       Date:  2013-07-31       Impact factor: 8.775

6.  Management of Inflammatory Bowel Disease during Pregnancy and Breastfeeding Varies Widely: A Need for Further Education.

Authors:  Vivian Wai-Mei Huang; Hsiu-Ju Chang; Karen Ivy Kroeker; Karen Jean Goodman; Kathleen M Hegadoren; Levinus Albert Dieleman; Richard Neil Fedorak
Journal:  Can J Gastroenterol Hepatol       Date:  2016-09-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.